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Abbreviations: 21 
BPD  beclometasone equivalent dose 22 
ECP  eosinophilic cationic protein 23 
FeNO  Fractional exhaled nitric oxide 24 
FEV1  Forced expiratory volume in 1 second 25 
IL-5  Interleukin-5 26 
ICS  Inhaled corticosteroid 27 
LTRA  Leukotriene receptor antagonist 28 
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Blood eosinophil counts which were once regarded as normal, have become of increasing 39 
interest in the era of Interluekin-5 (IL-5) asthma treatment. Blood eosinophils as low as 150 40 
cells/µL have been suggested as treatment cut-offs for eosinophil depleting therapies such as 41 
mepolizumab [1], whilst a value of 300 cells/µL has been deemed a more pragmatic cut off by 42 
the National Institute for Health and Care Excellence (United Kingdom). In this era of eosinophil 43 
post-truths, inhaled corticosteroids (ICS), the eosinophil’s oldest adversary, are very much the 44 
forgotten man.  45 
Corticosteroids reduce the numbers of eosinophils in blood and sputum by inhibiting the 46 
expression of pro eosinophilic cytokines such as IL-5, and increase the rate of apoptosis and 47 
associated phagocytosis. It is known that titrating ICS against sputum eosinophils results in 48 
improved asthma control[2]. Whilst it is also known that sputum eosinophils correlate well with 49 
blood eosinophils [3], the effects of increasing ICS dose on blood eosinophils are less well 50 
documented [4].  51 
We therefore wanted to know if ICS dose titration suppresses blood eosinophil counts in patients 52 
with persistent asthma. In addition, we investigated whether leukotriene receptor antagonists 53 
(LTRA) has a similar effect when used as add on therapy. Another surrogate marker of TH2 54 
mediated inflammation is exhaled breath nitric oxide (FeNO), where it has already been 55 
demonstrated that there is a dose-response effect of ICS[5]. 56 
We, therefore, performed a pooled analysis of our own studies performed by the Scottish Centre 57 
for Respiratory Research, where we measured blood eosinophils and FeNO from a baseline of 58 
none or low dose ICS to medium dose ICS with or without LTRA. Fourteen studies were 59 
included in this analysis, and are listed in table 1. All were approved by the East of Scotland 60 
Regional Ethics Committee and registered at clinicaltrials.gov.  61 
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217 non-smoking patients with mild-moderate persistent asthma patients were included in the 62 
ICS dose titration analysis, of these 144 also received additive LTRA. Patients had a mean age of 63 
38 years, and a mean FEV1 of 85% predicted. In all studies analysed patients must have been 64 
free from an asthma exacerbation requiring systemic corticosteroids in the three months prior to 65 
trial enrolment. In the nine out of fourteen studies included, patients had at least one positive skin 66 
prick test to a common aeroallergen, with a mean number of positive tests of two.  67 
Baseline median low dose inhaled corticosteroid (ICS) dose was 200µg/day as beclometasone 68 
diproprionate (BDP) equivalent dose .Baseline mean eosinophils were 356 cells/µL, mean 69 
eosinophilic cationic protein (ECP) was 24.9 µg/L, and mean exhaled nitric oxide (FeNO) was 70 
41.4 ppb. Participants were stepped up to medium dose ICS as median 800 µg/day BDP 71 
equivalent, with a median treatment duration of two weeks. Median treatment duration of 72 
additive LTRA was also two weeks.  73 
Changes in blood eosinophils and FeNO are presented in figure 1. We observed a significant 74 
mean fall in eosinophils of 71 cells/µL (95% CI 38 to 105) p=0.001 comparing low versus 75 
medium dose ICS, and a further non-significant fall with LTRA amounting to 20 cells/µL. FeNO 76 
also significantly fell by 14.5ppb (95% CI 7.9 to 21.1), p=0.001 comparing low and medium 77 
dose ICS, but did not decrease further with addition of LTRA.  Mean ECP levels for low and 78 
medium dose ICS were 24.9 µg/L and 18.8 µg/L respectively, representing a significant 79 
(p=0.005) decrease of 6.1 µg/L (95% CI 2.4 to 9.6), although, there were insufficient data to 80 
assess effects of LTRA. FEV1% predicted did not significantly change between low and medium 81 
dose ICS: 1.6% (95% CI -0.5 to 3.2).  82 
We demonstrated that ICS even at a medium dose of 800ug BDP results in a significant fall in 83 
blood eosinophils over a period of two weeks. Our data showed a non-significant further fall in 84 
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blood eosinophils amounting to 20 cells/µL when adding LTRA, while Laviolette et al found a 85 
significant additive effect of LTRA amounting to a mean change of 40 cells [6]. In contrast 86 
Greene et al found no significant additive fall with LTRA on top of ICS , albeit measuring 87 
sputum rather than blood eosinophils[7]. Their study also found no significant additive effect on 88 
FeNO in keeping with our data. In terms of ICS dose response, Kips et al reported significantly 89 
lower sputum eosinophils comparing medium and low dose ICS, but no commensurate fall in 90 
sputum ECP [8] , in contrast to our observation of a significant fall in both blood eosinophils and 91 
ECP.   92 
In a retrospective observational cohort study, Price et al. demonstrated that those with 93 
eosinophils ≥400 cells/µL experience more severe exacerbations and have worse asthma control 94 
[9]. The fundamental question therefore is whether ICS dose should be titrated against blood 95 
eosinophils as a surrogate inflammatory marker, especially given that pulmonary function shows 96 
a plateau in response above 400ug/day BDP equivalent dose [10]. In this regard Green et al 97 
showed that titrating ICS against sputum eosinophils resulted in significantly reduced 98 
exacerbations [2]; whether the same outcome would be achieved by titrating against blood 99 
remains to be answered.  We appreciate the limitations of our data which were only short term 100 
and we did not report any outcomes of asthma control. Furthermore, the observed effect might be 101 
due to possible systemic absorption from the lung, assessment of which would have required a 102 
surrogate marker of systemic cortisol suppression. Finally, our study lacks a placebo arm or a 103 
control arm with a fixed ICS dose, meaning we are unable to account for natural variation in 104 
blood eosinophils over time. In a more sever cohort of asthma patients, it has been demonstrated 105 
for subjects who have an initial blood eosinophil count above 150 cells/µl, 85% of them remain 106 
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above this value, even up to 56 weeks (based on four weekly blood eosinophil measurements) 107 
[11].  108 
As we consider ever more complex anti-inflammatory therapies as the future of asthma care, we 109 
must not overlook inhaled corticosteroids and their effects on blood eosinophils as the forgotten 110 
man of asthma therapy. Perhaps a randomized control trial comparing ICS dose titration against 111 
conventional markers (pulmonary function, reliever use, and symptoms) versus titration against 112 
blood eosinophils over one year might be worth pursuing. 113 
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 171 
Figure legend 172 
Comparison of low (200ug BDP equivalent) and medium dose (800ug BDP equivalent) inhaled 173 
corticosteroid (ICS) on blood eosinophils (top) and exhaled breath nitric oxide (bottom) in n=217 174 
asthma patients, depicted as means and SEM. Effects of add on therapy with leukotriene receptor 175 
antagonists (LTRA) are also shown in 144 patients. 176 
 177 
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Table 1. Source data   
Reference ICS dose 
(BDP µg 
equivalent) 
Total 
Exposure  
(days) 
1. Lipworth BJ et al. Am J Med 2000; 109:114-21. 600µg +/- LTRA 14 
2. Aziz I et al. Chest 2000; 118:1049-58. 400-800ug  28 
3. Wilson AM et al Chest 2001; 119:1021-6. 800µg +/-LTRA 14 
4. Dempsey OJ et al. J Allergy Clin Immunol 2002; 
109:68-74. 
0-400µg 28 
5. Currie GP et al. Am J Respir Crit Care Med 2003; 
167:1232-8. 
500µg-1000µg 21 
6. Currie GP et al. Allergy 2003; 58:602-7. 0-400µg 14 
7. Sims EJ et al. Br J Clin Pharmacol 2003; 56:104-11. 500µg +/-LTRA 14 
8. Anderson WJ et al. Clin Sci (Lond) 2014; 127:635-43. 200 -800µg 42 
9. Anderson WJ et al. Chest 2012; 142:1553-61. 200-1000µg 28 
10. Lipworth BJ et al. Chest 2012; 141:607-15. 400-1200µg 365 
11. Menzies D et al. Allergy 2007; 62:661-7. 
200-800µg+/-
LTRA 
35 
12. Barnes ML et al. Allergy 2007; 62:73-80. 0-400µg 70 
13. Dempsey OJ et al. Chest 2002; 122:151-9. 
100-400µg +/-
LTRA 
42 
14. Wilson AM et al. Br J Clin Pharmacol 1999; 48:579-85. 1000-2000µg 8 
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Figure legend  
Comparison of low (200ug BDP equivalent) and medium dose (800ug BDP equivalent) inhaled corticosteroid 
(ICS) on blood eosinophils (top) and exhaled breath nitric oxide (bottom) in n=217 asthma patients, 
depicted as means and SEM. Effects of add on therapy with leukotriene receptor antagonists (LTRA) are also 
shown in 144 patients.  
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